Genetic variation in CYP11A1 and StAR in relation to endometrial cancer risk

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 255-259

  Terry, Kathryn ^a,b   McGrath, Monica ^a,b   Lee, I Min ^a,b   Buring, Julie ^a,b   De Vivo, Immaculata ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CYP11A1; Endometrial cancer; Polymorphism; StAR

Indexed keywords

CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); ESTRADIOL; STEROIDOGENIC ACUTE REGULATORY PROTEIN;

ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CASE-CONTROL STUDIES; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTRONE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MIDDLE AGED; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950189684     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.002     Document Type: Article

References (46)

1. Key T.J., and Pike M.C. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57 2 (1988) 205-212
2. Henderson B.E., and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 21 3 (2000) 427-433
3. Kelsey J.L., LiVolsi V.A., Holford T.R., Fischer D.B., Mostow E.D., Schwartz P.E., O'Connor T., and White C. A case-control study of cancer of the endometrium. Am J Epidemiol 116 2 (1982) 333-342
4. Herrinton L.J., and Weiss N.S. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol 3 3 (1993) 308-318
5. Kaaks R., Lukanova A., and Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11 12 (2002) 1531-1543
6. Yager J.D., and Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36 (1996) 203-232
7. Zhu B.T., and Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19 1 (1998) 1-27
8. Liehr J.G., Roy D., Ari-Ulubelen A., Bui Q.D., Weisz J., and Strobel H.W. Effect of chronic estrogen treatment of Syrian hamsters on microsomal enzymes mediating formation of catecholestrogens and their redox cycling: implications for carcinogenesis. J Steroid Biochem 35 5 (1990) 555-560
9. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 21 1 (2000) 40-54
10. Jefcoate C.R., Liehr J.G., Santen R.J., Sutter T.R., Yager J.D., Yue W., Santner S.J., Tekmal R., Demers L., Pauley R., Naftolin F., Mor G., and Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27 (2000) 95-112
11. Banno K., Yanokura M., Kobayashi Y., Kawaguchi M., Nomura H., Hirasawa A., Susumu N., and Aoki D. Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). Curr Genomics 10 2 (2009) 127-132 PMC2699824
12. Gruber S.B., and Thompson W.D. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 5 6 (1996) 411-417
13. Parazzini F., La Vecchia C., Moroni S., Chatenoud L., and Ricci E. Family history and the risk of endometrial cancer. Int J Cancer 59 4 (1994) 460-462
14. De Vivo I., Persson I., and Adami H.O. Endometrial cancer. In: Adami H.O., Hunter D.J., and Trichopoulos D. (Eds). Textbook of Cancer Epidemiology (2008), Oxford University Press 468-493
15. Caron K.M., Soo S.C., Wetsel W.C., Stocco D.M., Clark B.J., and Parker K.L. Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci U S A 94 21 (1997) 11540-11545
16. Hu M.C., Hsu N.C., El Hadj N.B., Pai C.I., Chu H.P., Wang C.K., and Chung B.C. Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1. Mol Endocrinol 16 8 (2002) 1943-1950
17. Escobedo L.G., Lee N.C., Peterson H.B., and Wingo P.A. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 77 1 (1991) 124-128
18. Coulam C.B., Annegers J.F., and Kranz J.S. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61 4 (1983) 403-407
19. Bose H.S., Sugawara T., Strauss III J.F., and Miller W.L. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 335 25 (1996) 1870-1878
20. Conte FA and Grumbach MM, Abnormalities of Sexual Determination & Differentiation, in Greenspan's Basic and Clinical Endocrinology, D. Gardner and D. Shoback, Editors, Lange Medical Books/McGraw-Hill. p. 509-549.
21. Lin D., Sugawara T., Strauss III J.F., Clark B.J., Stocco D.M., Saenger P., Rogol A., and Miller W.L. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267 5205 (1995) 1828-1831
22. Diamanti-Kandarakis E., Bartzis M.I., Bergiele A.T., Tsianateli T.C., and Kouli C.R. Microsatellite polymorphism (tttta)(n) at - 528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 73 4 (2000) 735-741
23. Gharani N., Waterworth D.M., Batty S., White D., Gilling-Smith C., Conway G.S., McCarthy M., Franks S., and Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 6 3 (1997) 397-402
24. Pugeat M., Ducluzeau P.H., Pugeat M., and Ducluzeau P.H. Insulin resistance, polycystic ovary syndrome and metformin. Drugs 58 1 (1999) 41-46 discussion 75-82
25. Pusalkar M., Meherji P., Gokral J., Chinnaraj S., and Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril (2008)
26. Sugawara T., Nomura E., and Fujimoto S. Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells. J Endocrinol 180 1 (2004) 135-144
27. Zheng W., Gao Y.T., Shu X.O., Wen W., Cai Q., Dai Q., and Smith J.R. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 13 5 (2004) 709-714
28. Yaspan B.L., Breyer J.P., Cai Q., Dai Q., Elmore J.B., Amundson I., Bradley K.M., Shu X.O., Gao Y.T., Dupont W.D., Zheng W., and Smith J.R. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. Cancer Res 67 12 (2007) 5673-5682
29. Sakoda L.C., Blackston C., Doherty J.A., Ray R.M., Lin M.G., Stalsberg H., Gao D.L., Feng Z., Thomas D.B., and Chen C. Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 17 5 (2008) 1066-1073
30. Setiawan V.W., Cheng I., Stram D.O., Giorgi E., Pike M.C., Van Den Berg D., Pooler L., Burtt N.P., Le Marchand L., Altshuler D., Hirschhorn J., Henderson B.E., and Haiman C.A. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer. Cancer Res 66 24 (2006) 12019-12025
31. Olson S.H., Orlow I., Bayuga S., Sima C., Bandera E.V., Pulick K., Faulkner S., Tommasi D., Egan D., Roy P., Wilcox H., Asya A., Modica I., Asad H., Soslow R., and Zauber A.G. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 19 9 (2008) 955-963
32. He C., Kraft P., Chen C., Buring J.E., Pare G., Hankinson S.E., Chanock S.J., Ridker P.M., Hunter D.J., and Chasman D.I. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet (2009)
33. King I.B., Satia-Abouta J., Thornquist M.D., Bigler J., Patterson R.E., Kristal A.R., Shattuck A.L., Potter J.D., and White E. Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev 11 10 Pt 1 (2002) 1130-1133
34. Missmer S.A., Eliassen A.H., Barbieri R.L., and Hankinson S.E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96 24 (2004) 1856-1865
35. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., and Buring J.E. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Jama 294 1 (2005) 47-55
36. Lee I.M., Cook N.R., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., and Buring J.E. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. Jama 294 1 (2005) 56-65
37. Rexrode K.M., Lee I.M., Cook N.R., Hennekens C.H., and Buring J.E. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9 1 (2000) 19-27
38. Excoffier L., and Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12 5 (1995) 921-927
39. Tranah G.J., Lescault P.J., Hunter D.J., and De Vivo I. Multiple displacement amplification prior to single nucleotide polymorphism genotyping in epidemiologic studies. Biotechnol Lett 25 13 (2003) 1031-1036
40. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., and Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90 17 (1998) 1292-1299
41. Zaykin D.V., Westfall P.H., Young S.S., Karnoub M.A., Wagner M.J., and Ehm M.G. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 53 2 (2002) 79-91
42. Rosner B. Percentage points for generalized ESD many-outlier procedure. Technometrics 25 (1983) 165-172
43. McGrath M., Lee I.M., Hankinson S.E., Kraft P., Hunter D.J., Buring J., and De Vivo I. Androgen receptor polymorphisms and endometrial cancer risk. Int J Cancer 118 5 (2006) 1261-1268
44. Daneshmand S., Weitsman S.R., Navab A., Jakimiuk A.J., and Magoffin D.A. Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17-20) lyase promoters. Fertil Steril 77 2 (2002) 274-280
45. Gaasenbeek M., Powell B.L., Sovio U., Haddad L., Gharani N., Bennett A., Groves C.J., Rush K., Goh M.J., Conway G.S., Ruokonen A., Martikainen H., Pouta A., Taponen S., Hartikainen A.L., Halford S., Jarvelin M.R., Franks S., and McCarthy M.I. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 89 5 (2004) 2408-2413
46. Garcia-Closas M., Herbstman J., Schiffman M., Glass A., and Dorgan J.F. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 102 2 (2002) 172-178